Health

Beyond Clinical Trials: Patients Report Lingering Effects Following Psychedelic Treatment

While psychedelic drugs show promise for treating mental health conditions, researchers and patients warn that more attention is needed for those who experience persistent difficulties after treatment concludes.

As the Food and Drug Administration potentially moves toward approving psychedelics for mental health treatment, researchers and patient advocates are calling for a greater focus on the minority of patients who experience persistent distress in the aftermath of these sessions.

While clinical trials for drugs such as psilocybin and MDMA are heralded for their potential to address treatment-resistant depression and other mental health conditions, experts suggest the focus on initial outcomes may be obscuring the reality for some patients who struggle long after the drugs have worn off.

For some participants, the treatment process has been complex. One patient, who requested to be identified only as “Sin” due to concerns about her professional life, participated in a clinical trial for 5-MeO-DMT for treatment-resistant depression. While the treatment helped lift her persistent depression, she found the subsequent recovery phase agonizing and unpredictable.

“Like a very thin skin almost to your emotions,” she said of her recovery, noting that her symptoms shifted from depression to intense anxiety and panic attacks. Sin described the experience as isolating, as she questioned whether the trial had been the right decision.

Similar concerns were raised by Laura Zam, whose husband, Kurt, participated in an MDMA trial for cancer survivors and their caregivers. While he initially reported feeling elated, Zam observed significant behavioral shifts shortly after, including severe insomnia, obsessive rumination, and worry. Over the subsequent six months, the situation worsened until he required institutionalization five times due to suicidal ideation. Zam said those involved in his care appeared to lack the necessary understanding of potential negative consequences associated with the therapy.

Pedram Dara, who faced his own complications following MDMA-assisted therapy in a Canadian clinical trial, has established a patient-led initiative called Psychedelic Lived Experiences. Dara emphasizes that the nature of these treatments is not binary—patients are not simply either “cured” or “harmed.” He notes that a “safe session or safe dosing session doesn’t mean safe outcome.”

Dr. Roman Palitsky, a research psychologist at Emory University School of Medicine, confirms that his team hears from patients regarding these persistent difficulties on a regular basis. He notes that while psychedelic therapies are effective for many, it is necessary to be candid about potential adverse effects. Current clinical trials track serious events, such as prolonged psychotic episodes or suicidality, but Palitsky argues that there are significant blind spots, including insufficient follow-up periods and a failure to capture the full spectrum of experiences, such as dissociation or existential distress.

Jules Evans, director of the Challenging Psychedelic Experiences Project, a nonprofit dedicated to researching these issues, suggests that many providers of legal psychedelic treatments are often unaware of the potential for persistent complications that can emerge weeks or months after treatment. For patients like Sin, the recovery process remains a long, sometimes agonizing endeavor. As the medical community moves toward wider availability, she stresses that the unpredictability of these treatments is a crucial factor that remains underappreciated.

Evelyn Price

Evelyn Price covers health news, medical research, public health developments, and wellness topics. She aims to present evidence-based information in clear language, helping readers understand important studies, health policies, and advances in medicine.
Back to top button